Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer
Histopathology · 2026-09 · 89 (3) · 456-466
DOI: 10.1111/his.70168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 09.06.2026. Verfasst von Alexis B Cortot und 14 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille, CHU Lille…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-met, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Aims
The c‐Met signalling pathway is dysregulated in non‐small cell lung cancer (NSCLC), with c‐Met protein overexpression emerging as a potentially actionable biomarker given the development of c‐Met‐targeted antibody‐drug conjugates. This retrospective study assessed the consistency of c‐Met protein overexpression over time in patients with non‐squamous NSCLC and two or more longitudinal biopsy samples (one before treatment, one post‐treatment). Methods and results Samples from 160 patients were analysed for c‐Met protein expression. The concordance rate for c‐Met protein overexpression between samples was 81.3%, indicating most patients had consistent expression status. Patients with an EGFR mutation had a lower concordance rate (65.8%). Fourteen patients with high discordance (negative to positive) between sampling time points showed a high frequency of oncogenic driver alterations, hence often received targeted therapy before the second sample and had high percentages of cells at 2+ intensity in c‐Met immunohistochemistry before treatment.
Conclusions
These results indicate c‐Met protein overexpression can be assessed before or after treatment since most patients maintain consistent c‐Met status. As targeted therapies may elevate c‐Met overexpression over time, retesting may be necessary in those with an oncogenic driver alteration initially diagnosed as c‐Met negative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille, CHU Lille, Lille, France.
- Institute of Pathology, CHU Lille, Lille, France.
- Department of Biostatistics, CHU Lille, Lille, France.
- Department of Thoracic Oncology, CHU Lille, Lille, France.
- AbbVie Inc, North Chicago, Illinois, USA.
ORCID-Profile: Alexis B Cortot, Romain Dubois, Valérie Grégoire, Jean-Baptiste Gibier, Julien Labreuche, Virginie Deprez, Déborah Dubrulle, Thomas Chretien, Eric Wasielewski, Hélène Behal, Dai Feng, Amber Lind, Peter Ansell, Raphaële Thiébaut-Millot, Carlos Hader
Förderung
- AbbVie
Zitieren
APA
Cortot, A. B., Dubois, R., Grégoire, V., Gibier, J. B., Labreuche, J., Deprez, V., Dubrulle, D., Chretien, T., Wasielewski, E., Behal, H., Feng, D., Lind, A., Ansell, P., Thiébaut-Millot, R., & Hader, C. (2026). Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer. Histopathology, 89(3), 456-466. https://doi.org/10.1111/his.70168
Vancouver
Cortot AB, Dubois R, Grégoire V, Gibier JB, Labreuche J, Deprez V, et al. Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer. Histopathology. 2026;89(3):456-466. doi:10.1111/his.70168
BibTeX
@article{Cortot2026,
author = {Cortot, Alexis B and Dubois, Romain and Grégoire, Valérie and Gibier, Jean-Baptiste and Labreuche, Julien and Deprez, Virginie and Dubrulle, Déborah and Chretien, Thomas and Wasielewski, Eric and Behal, Hélène and Feng, Dai and Lind, Amber and Ansell, Peter and Thiébaut-Millot, Raphaële and Hader, Carlos},
title = {Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer},
journal = {Histopathology},
year = {2026},
volume = {89},
number = {3},
pages = {456--466},
doi = {10.1111/his.70168}
}
EUVIMED